Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. Chemotherapy. Radiation. Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Survival: 16.1 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: Switzerland
City/State/Province: Lausanne
Hospital: Centre Hospitalier Universitaire Vaudois
Journal: Link
Date: 6/2010

This study involved 52 patients with newly diagnosed glioblastoma. The median age of the patients was 57 years and 62% were male. Patients had not received prior chemotherapy or radiotherapy.

Patients were treated with a combination of radiotherapy, the chemotherapy agent temozolomide, and a biologic agent called cilengitide, which targets cellular proteins called integrins to inhibit cancer cell signaling and growth.

The most common toxicity in this study was lymphocytopenia, and 56% patients experienced grade 3 or 4. Other grade 3 or 4 toxicities included thrombocytopenia (14% of patients), headache (6%), and fatigue (4%). There were no study-related deaths reported.

Median overall survival rate in this study was 16.1 months. Median progression-free survival was 8 months.

This study was supported by Merck, the company that manufactures cilengitide.

Correspondence: Dr. Roger Stupp; email:

E-mail to a Friend Email Physician More Information